
About Metagen Therapeutics
Metagen Therapeutics is a Healthcare company based in Tokyo (Japan) founded in 2020 by Shinji Fukuda, Takuji Yamada, Masatsugu Fukuda, Taku Nakahara, and Dai Ishikawa. CRO focused on providing microbiome drug discovery and development services. Metagen Therapeutics has raised $38.61 million across 10 funding rounds from investors including Keio Innovation Initiative, JAFCO and JIC Venture Growth Investments. Its chief executive, as recorded, is Taku Nakahara. Its website metagentx.com draws about 10 thousand monthly visits. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Cell and Molecular Biology.
Company details
Metagen Therapeutics was established in 2020 in Tokyo, Japan, as a contract research organization (CRO) specializing in the microbiome sector. Drug discovery and development services for microbiome-based therapeutics are delivered to clients in the pharmaceutical industry. Operations center on advanced research methodologies to identify and validate microbial targets. The companys activities support early-stage to preclinical pipeline advancement, with a focus on therapeutic applications in human health.
- Headquarters Tokyo, Japan
- Founders Shinji Fukuda, Takuji Yamada, Masatsugu Fukuda, Taku Nakahara, Dai Ishikawa
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website metagentx.com
- Social LinkedIn X Facebook
- Total Equity Funding$38.61M (USD)
in 10 rounds
- Latest Funding Round$1.87M (USD), Series B
Sep 2026
- InvestorsKeio Innovation Initiative
& 23 more
Funding Insights of Metagen Therapeutics
Metagen Therapeutics has successfully raised a total of $38.61M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $1.87 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $38.61M
- Total Rounds 10
- Last Round Series B β $1.87M
- First Round $827,640
(Mar 2021)
- Investors Count 24
All 10 funding rounds of Metagen Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2026 | $1.87M | Series B | β | β | |
| Sep 2026 | $1.28M | Series B | β | β | |
| Feb 2026 | $7.62M | Series B | β | β | |
| Sep 2025 | $15.72M | Series B | β | FTI | |
| Jul 2025 | $10.24M | Series B | β | β | β |
| Jun 2023 | Series A | β | JAFCO Group, FTI | ||
| Apr 2023 | Seed | β | JIC Venture Growth Investments | β | |
| Jul 2022 | $679,000 | Seed | β | β | β |
| Jun 2022 | $372,750 | Seed | β | β | β |
| Mar 2021 | $827,640 | Seed | β | β | β |
24 investors in total: 24 institutional.
Investors in Metagen Therapeutics
Metagen Therapeutics has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Keio Innovation Initiative, JAFCO and JIC Venture Growth Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on growth stage companies | j-vgi.co.jp | Minato City, Japan | ||
| fasttrackinitiative.com | ||||
Stage-agnostic investments in Japanese tech and life sciences are made. | 2015 | keio-innovation.co.jp | Tokyo, Japan | |
PE and VC fund focused on multiple sectors | 1973 | jafco.co.jp/english | Singapore, Singapore | |
| mizuho-vc.co.jp | ||||
| smbc-vc.co.jp | ||||
Venture capital investments are made in research-driven startups. | 2014 | miraisozo.co.jp | Tokyo, Japan | |
Venture capital firm investing in global startups with a focus on innovation and business support. | dentsu-v.com | |||
| fvc.co.jp | ||||
| nvcc.co.jp |
Investor details for Metagen Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Metagen Therapeutics
5 people are tracked at Metagen Therapeutics (5 in leadership).
| Name | Role | Group |
|---|---|---|
Shinji Fukuda | Co-Founder | Leadership |
Takuji Yamada | Co-Founder & CTO | Leadership |
Masatsugu Fukuda | Co-Founder | Leadership |
Taku Nakahara | Co-Founder & CEO | Leadership |
Dai Ishikawa | Co-Founder & CMO | Leadership |
Complete people profiles for Metagen Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Metagen Therapeutics
3 dated milestones of Metagen Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Metagen Therapeutics is founded.
- Funding First funding round of $828K.
- Funding Latest funding round, Series B, of $1.9M.
Web traffic of Metagen Therapeutics
The website of Metagen Therapeutics (metagentx.com) receives about 10.1K visits a month.
- Monthly visits10.1K
▲ 33.8% vs previous month
Websites whose visitors overlap most with Metagen Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| digireha.com | 100% | 3.2K | #5,653,338 | View details | |
| metagen.co.jp | 72% | 7.3K | #2,679,295 | View details | |
storynews.jp | storynews.jp | 60% | #3,704,544 | β | |
kindai-geka.jp | kindai-geka.jp | 27% | #2,473,473 | β | |
22cemit.org | 22cemit.org | 26% | #6,258,342 | β |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Metagen Therapeutics
Complete news archive for Metagen Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Metagen Therapeutics
Metagen Therapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Metagen Therapeutics is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Taku Nakahara is the CEO of Metagen Therapeutics, as recorded in our data. They have also founded this company.
Metagen Therapeutics is a funded company, having raised a total of $38.61M across 10 funding rounds to date. The company's 1st funding round was a Seed of $827.64K, raised on Mar 2021.
Metagen Therapeutics was established in 2020 in Tokyo, Japan, as a contract research organization (CRO) specializing in the microbiome sector. Drug discovery and development services for microbiome-based therapeutics are delivered to clients in the pharmaceutical industry. Operations center on advanced research methodologies to identify and validate microbial targets. The companys activities support early-stage to preclinical pipeline advancement, with a focus on therapeutic applications in human health.
Metagen Therapeutics has 24 investors. Key investors include Keio Innovation Initiative, JAFCO, JIC Venture Growth Investments, JAFCO Group, and FTI.
